Trial Profile
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
- Indications Aspergillosis; Blastomycosis; Coccidioidomycosis; Cryptococcosis; Histoplasmosis; Invasive bronchopulmonary aspergillosis; Mycoses; Paracoccidioidomycosis
- Focus Registrational; Therapeutic Use
- Acronyms VICAL; VITAL
- Sponsors Astellas Pharma; Basilea Pharmaceutica
- 14 Dec 2021 Results Post-Hoc Analysis from the VITAL and SECURE, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 29 Apr 2021 Results of post-hoc analysis of two studies (SECURE & VITAL) published in the Clinical Infectious Diseases.
- 19 Nov 2020 Data were used from SECURE and VITAL studies to assess Cost-Effectiveness of Isavuconazole in the Treatment of Invasive Fungal Infections in Portugal presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research